Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963889 | 0.87 | MKNK1 (0.67) | MKNK1EGFRERBB2RETBRAF | |
| SCHEMBL16963582 | 0.85 | MKNK1 (0.60) | MKNK1EGFRERBB2RETCDC7 | |
| SCHEMBL16371846 | 0.84 | BRAF (0.48) | MKNK1EGFRERBB2BRAFTNNI3K | |
| SCHEMBL16963700 | 0.83 | MKNK1 (0.60) | MKNK1EGFRERBB2RETCDC7 | |
| SCHEMBL12655524 | 0.83 | MKNK1 (0.60) | MKNK1EGFRERBB2RETCDC7 | |
| SCHEMBL16968171 | 0.83 | MKNK1 (0.60) | MKNK1EGFRERBB2RETCDC7 | |
| SCHEMBL16372321 | 0.82 | AKT1 (0.46) | MKNK1EGFRERBB2BRAFTNNI3K | |
| SCHEMBL16963873 | 0.82 | MKNK1 (0.59) | MKNK1EGFRERBB2RETBRAF | |
| SCHEMBL16963643 | 0.81 | MKNK1 (0.58) | MKNK1EGFRERBB2RETBRAF | |
| SCHEMBL16963340 | 0.80 | MKNK1 (0.67) | MKNK1EGFRERBB2RETCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | MKNK1 2957/4885EGFR 3423/4885ERBB2 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.